To date, the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib have been approved for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic BC in combination with an endocrine therapy1. This evidence concerns the gene ERBB2 and breast cancer.